Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02294032 · ClinicalTrials.gov registry record

The Role of B Cells in Kidney Allograft Dysfunction

A clinical trial of Transplantation Infection and Kidney; Complications, Allograft, sponsored by Loma Linda University.

Completed
Registry status
180
Enrollment target
1
Study location

NCT02294032 is a study of Transplantation Infection and Kidney; Complications, Allograft that has completed, run by Loma Linda University. The registered enrollment target is 180 participants, below the 251-participant average among 4 other Transplantation Infection trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02294032, a study of Transplantation Infection and Kidney; Complications, Allograft, has completed, sponsored by Loma Linda University.

COMPLETED
Registry status
180 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to understand the role of specific B cells in activating or repressing an anti-allograft immune response after kidney transplantation. In this study, blood will be collected from kidney transplant patients during different timepoints, prior to and after their transplant. Knowledge gained from study findings will be used to develop therapeutic strategies to prevent antibody-mediated rejection, which is a major cause of long-term graft loss in kidney transplant patients.

Interventions

  • DRUG Immunosuppressive Agents

Study Locations (1)

California

  • Loma Linda University Medical Center, Transplantation Institute - Loma Linda

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2014-08-28
Est. Completion 2023-04-24

Sponsor

Loma Linda University

237 total trials

What the Registry Record Tells You About NCT02294032

The ClinicalTrials.gov registry entry for NCT02294032 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 251-participant average among 4 other Transplantation Infection trials with a reported enrollment target (28% lower). The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Transplantation Infection appearing as the primary indexed condition, and to 1 intervention - of which Immunosuppressive Agents is the first listed.

NCT02294032 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02294032 about?

NCT02294032 is a clinical study titled "The Role of B Cells in Kidney Allograft Dysfunction". The purpose of this study is to understand the role of specific B cells in activating or repressing an anti-allograft immune response after kidney transplantation. In this study, blood will be collected from kidney transplant patients during different timepoints, prior to and after their transplant....

What is the current status of trial NCT02294032?

This trial is currently completed. The enrollment target is 180 participants. The study started on 2014-08-28. Estimated completion is 2023-04-24.

What conditions does trial NCT02294032 study?

This clinical trial studies the following conditions: Transplantation Infection, Kidney; Complications, Allograft.

What interventions are being tested in trial NCT02294032?

The interventions under investigation include: Immunosuppressive Agents (DRUG).

Who is sponsoring clinical trial NCT02294032?

This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02294032 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Transplantation Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.